Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 39 entries
Sorted by: Best Match Show Resources per page
Involvement of PPARγ in the protective action of tropisetron in an experimental model of ulcerative colitis.

Immunopharmacology and immunotoxicology

Rahimian R, Zirak MR, Keshavarz M, Fakhraei N, Mohammadi-Farani A, Hamdi H, Mousavizadeh K.
PMID: 27644482
Immunopharmacol Immunotoxicol. 2016 Dec;38(6):432-440. doi: 10.1080/08923973.2016.1231202. Epub 2016 Sep 20.

Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal (GI) tract. Tropisetron, a selective 5-HT

Cite
Rahimian R, Zirak MR, Keshavarz M, et al. Involvement of PPARγ in the protective action of tropisetron in an experimental model of ulcerative colitis. Immunopharmacol Immunotoxicol. 2016;38(6):432-440doi: 10.1080/08923973.2016.1231202.
Rahimian, R., Zirak, M. R., Keshavarz, M., Fakhraei, N., Mohammadi-Farani, A., Hamdi, H., & Mousavizadeh, K. (2016). Involvement of PPARγ in the protective action of tropisetron in an experimental model of ulcerative colitis. Immunopharmacology and immunotoxicology, 38(6), 432-440. https://doi.org/10.1080/08923973.2016.1231202
Rahimian, Reza, et al. "Involvement of PPARγ in the protective action of tropisetron in an experimental model of ulcerative colitis." Immunopharmacology and immunotoxicology vol. 38,6 (2016): 432-440. doi: https://doi.org/10.1080/08923973.2016.1231202
Rahimian R, Zirak MR, Keshavarz M, Fakhraei N, Mohammadi-Farani A, Hamdi H, Mousavizadeh K. Involvement of PPARγ in the protective action of tropisetron in an experimental model of ulcerative colitis. Immunopharmacol Immunotoxicol. 2016 Dec;38(6):432-440. doi: 10.1080/08923973.2016.1231202. Epub 2016 Sep 20. PMID: 27644482.
Copy Download .nbib Format: NLM
Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting.

International journal of clinical and experimental medicine

Ma Y, Su L, Liu L, Xie C, Zhang X, Song B, Cheng S, Liu J.
PMID: 26221359
Int J Clin Exp Med. 2015 May 15;8(5):7989-94. eCollection 2015.

The purpose of the study was to evaluate the efficacy and toxicity of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting. A total of 82 non-small cell lung cancer patients undergoing Docetaxel combined with Cisplatin were randomly...

Cite
Ma Y, Su L, Liu L, et al. Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting. Int J Clin Exp Med. 2015;8(5):7989-94
Ma, Y., Su, L., Liu, L., Xie, C., Zhang, X., Song, B., Cheng, S., & Liu, J. (2015). Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting. International journal of clinical and experimental medicine, 8(5), 7989-94.
Ma, Yuan, et al. "Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting." International journal of clinical and experimental medicine vol. 8,5 (2015): 7989-94.
Ma Y, Su L, Liu L, Xie C, Zhang X, Song B, Cheng S, Liu J. Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting. Int J Clin Exp Med. 2015 May 15;8(5):7989-94. eCollection 2015. PMID: 26221359; PMCID: PMC4509304.
Copy Download .nbib Format: NLM
[Risk Factors associated with post-chemotherapy vomiting in patients with breast cancer (II): analysis of the duration of emesis].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Pérez Ruixo J, Llopis García M, Casabo Alos V, Jiménez Torres N.
PMID: 12595939
Farm Hosp. 2002 Sep-Oct;26(5):275-282.

OBJECTIVE: To identify the risk factors associated with the duration of emesis after high-dose chemotherapy in high risk breast cancer patients and to assess the predictive performance of a mathematical model. METHODS: Cox regression model was developed to predict...

Cite
Pérez Ruixo J, Llopis García M, Casabo Alos V, et al. Factores de riesgo asociados con la emesis postquimioterapia en pacientes con cáncer de mama (II): análisis de la duración de la émesis. [Risk Factors associated with post-chemotherapy vomiting in patients with breast cancer (II): analysis of the duration of emesis]. Farm Hosp. 2002;26(5):275-282
Pérez Ruixo, J., Llopis García, M., Casabo Alos, V., & Jiménez Torres, N. (2002). Factores de riesgo asociados con la emesis postquimioterapia en pacientes con cáncer de mama (II): análisis de la duración de la émesis. [Risk Factors associated with post-chemotherapy vomiting in patients with breast cancer (II): analysis of the duration of emesis]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 26(5), 275-282.
Pérez Ruixo, JJ, et al. "Factores de riesgo asociados con la emesis postquimioterapia en pacientes con cáncer de mama (II): análisis de la duración de la émesis." [Risk Factors associated with post-chemotherapy vomiting in patients with breast cancer (II): analysis of the duration of emesis]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria vol. 26,5 (2002): 275-282.
Pérez Ruixo J, Llopis García M, Casabo Alos V, Jiménez Torres N. Factores de riesgo asociados con la emesis postquimioterapia en pacientes con cáncer de mama (II): análisis de la duración de la émesis. [Risk Factors associated with post-chemotherapy vomiting in patients with breast cancer (II): analysis of the duration of emesis]. Farm Hosp. 2002 Sep-Oct;26(5):275-282. Spanish. PMID: 12595939.
Copy Download .nbib Format: NLM
Increased 5-HT(3)-mediated signalling in pelvic afferent neurons from mice deficient in P2X(2) and/or P2X (3) receptor subunits.

Purinergic signalling

Ma B, Wynn G, Dunn PM, Burnstock G.
PMID: 18404485
Purinergic Signal. 2006 Sep;2(3):481-9. doi: 10.1007/s11302-006-9017-z. Epub 2006 Jul 04.

Extracellular ATP and 5-hydroxytryptamine (5-HT) are both involved in visceral sensory pathways by interacting with P2X and 5-HT(3) receptors, respectively. We have investigated the changes in P2X and 5-HT(3)-mediated signalling in pelvic afferent neurons in mice deficient in P2X(2)...

Cite
Ma B, Wynn G, Dunn PM, et al. Increased 5-HT(3)-mediated signalling in pelvic afferent neurons from mice deficient in P2X(2) and/or P2X (3) receptor subunits. Purinergic Signal. 2006;2(3):481-9doi: 10.1007/s11302-006-9017-z.
Ma, B., Wynn, G., Dunn, P. M., & Burnstock, G. (2006). Increased 5-HT(3)-mediated signalling in pelvic afferent neurons from mice deficient in P2X(2) and/or P2X (3) receptor subunits. Purinergic signalling, 2(3), 481-9. https://doi.org/10.1007/s11302-006-9017-z
Ma, Bei, et al. "Increased 5-HT(3)-mediated signalling in pelvic afferent neurons from mice deficient in P2X(2) and/or P2X (3) receptor subunits." Purinergic signalling vol. 2,3 (2006): 481-9. doi: https://doi.org/10.1007/s11302-006-9017-z
Ma B, Wynn G, Dunn PM, Burnstock G. Increased 5-HT(3)-mediated signalling in pelvic afferent neurons from mice deficient in P2X(2) and/or P2X (3) receptor subunits. Purinergic Signal. 2006 Sep;2(3):481-9. doi: 10.1007/s11302-006-9017-z. Epub 2006 Jul 04. PMID: 18404485; PMCID: PMC2096651.
Copy Download .nbib Format: NLM
A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia.

Annals of general psychiatry

Shiina A, Shirayama Y, Niitsu T, Hashimoto T, Yoshida T, Hasegawa T, Haraguchi T, Kanahara N, Shiraishi T, Fujisaki M, Fukami G, Nakazato M, Iyo M, Hashimoto K.
PMID: 20573264
Ann Gen Psychiatry. 2010 Jun 24;9:27. doi: 10.1186/1744-859X-9-27.

BACKGROUND: Cognitive deficits in schizophrenia are associated with psychosocial deficits that are primarily responsible for the poor long-term outcome of this disease. Auditory sensory gating P50 deficits are correlated with neuropsychological deficits in attention, one of the principal cognitive...

Cite
Shiina A, Shirayama Y, Niitsu T, et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry. 2010;9:27doi: 10.1186/1744-859X-9-27.
Shiina, A., Shirayama, Y., Niitsu, T., Hashimoto, T., Yoshida, T., Hasegawa, T., Haraguchi, T., Kanahara, N., Shiraishi, T., Fujisaki, M., Fukami, G., Nakazato, M., Iyo, M., & Hashimoto, K. (2010). A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Annals of general psychiatry, 927. https://doi.org/10.1186/1744-859X-9-27
Shiina, Akihiro, et al. "A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia." Annals of general psychiatry vol. 9 (2010): 27. doi: https://doi.org/10.1186/1744-859X-9-27
Shiina A, Shirayama Y, Niitsu T, Hashimoto T, Yoshida T, Hasegawa T, Haraguchi T, Kanahara N, Shiraishi T, Fujisaki M, Fukami G, Nakazato M, Iyo M, Hashimoto K. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry. 2010 Jun 24;9:27. doi: 10.1186/1744-859X-9-27. PMID: 20573264; PMCID: PMC2901366.
Copy Download .nbib Format: NLM
Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human Subjects.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Ishikawa M, Sakata M, Toyohara J, Oda K, Ishii K, Wu J, Yoshida T, Iyo M, Ishiwata K, Hashimoto K.
PMID: 23430308
Clin Psychopharmacol Neurosci. 2011 Dec;9(3):111-6. doi: 10.9758/cpn.2011.9.3.111. Epub 2011 Dec 31.

OBJECTIVE: Agonists of α7-nicotinic acetylcholine receptors (nAChRs) have been developed as potential therapeutic drugs for neuropsychiatric diseases such as schizophrenia and Alzheimer's disease. Positron emission tomography (PET) is a noninvasive brain imaging technique to measure receptor occupancy in the...

Cite
Ishikawa M, Sakata M, Toyohara J, et al. Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human Subjects. Clin Psychopharmacol Neurosci. 2011;9(3):111-6doi: 10.9758/cpn.2011.9.3.111.
Ishikawa, M., Sakata, M., Toyohara, J., Oda, K., Ishii, K., Wu, J., Yoshida, T., Iyo, M., Ishiwata, K., & Hashimoto, K. (2011). Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human Subjects. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 9(3), 111-6. https://doi.org/10.9758/cpn.2011.9.3.111
Ishikawa, Masatomo, et al. "Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human Subjects." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 9,3 (2011): 111-6. doi: https://doi.org/10.9758/cpn.2011.9.3.111
Ishikawa M, Sakata M, Toyohara J, Oda K, Ishii K, Wu J, Yoshida T, Iyo M, Ishiwata K, Hashimoto K. Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human Subjects. Clin Psychopharmacol Neurosci. 2011 Dec;9(3):111-6. doi: 10.9758/cpn.2011.9.3.111. Epub 2011 Dec 31. PMID: 23430308; PMCID: PMC3569118.
Copy Download .nbib Format: NLM
The antiemetic effect of a novel tropisetron patch in anticancer agents-induced kaolin pica model using rats.

Environmental toxicology and pharmacology

Jeong SW, Cho JW, Hwang JS, Song JD, Shin S, Jang JY, Hwang SY, Kim O, Kim JC, Kim YB, Kang JK.
PMID: 21783585
Environ Toxicol Pharmacol. 2005 Jul;20(1):167-74. doi: 10.1016/j.etap.2004.12.065. Epub 2005 Feb 16.

The efficacy of a novel transdermal patch containing tropisetron, a 5-hydroxytryptamine 3 (5-HT(3)) receptor antagonist, against emesis induced by anticancer agents were evaluated, in comparison with the effect of traditional tropisetron injection, in rats. The antiemetic effects were assessed...

Cite
Jeong SW, Cho JW, Hwang JS, et al. The antiemetic effect of a novel tropisetron patch in anticancer agents-induced kaolin pica model using rats. Environ Toxicol Pharmacol. 2005;20(1):167-74doi: 10.1016/j.etap.2004.12.065.
Jeong, S. W., Cho, J. W., Hwang, J. S., Song, J. D., Shin, S., Jang, J. Y., Hwang, S. Y., Kim, O., Kim, J. C., Kim, Y. B., & Kang, J. K. (2005). The antiemetic effect of a novel tropisetron patch in anticancer agents-induced kaolin pica model using rats. Environmental toxicology and pharmacology, 20(1), 167-74. https://doi.org/10.1016/j.etap.2004.12.065
Jeong, Seung Wei, et al. "The antiemetic effect of a novel tropisetron patch in anticancer agents-induced kaolin pica model using rats." Environmental toxicology and pharmacology vol. 20,1 (2005): 167-74. doi: https://doi.org/10.1016/j.etap.2004.12.065
Jeong SW, Cho JW, Hwang JS, Song JD, Shin S, Jang JY, Hwang SY, Kim O, Kim JC, Kim YB, Kang JK. The antiemetic effect of a novel tropisetron patch in anticancer agents-induced kaolin pica model using rats. Environ Toxicol Pharmacol. 2005 Jul;20(1):167-74. doi: 10.1016/j.etap.2004.12.065. Epub 2005 Feb 16. PMID: 21783585.
Copy Download .nbib Format: NLM
Engineering a surrogate human heteromeric α/β glycine receptor orthosteric site exploiting the structural homology and stability of acetylcholine-binding protein.

IUCrJ

Dawson A, Trumper P, de Souza JO, Parker H, Jones MJ, Hales TG, Hunter WN.
PMID: 31709057
IUCrJ. 2019 Sep 04;6:1014-1023. doi: 10.1107/S205225251901114X. eCollection 2019 Nov 01.

Protein-engineering methods have been exploited to produce a surrogate system for the extracellular neurotransmitter-binding site of a heteromeric human ligand-gated ion channel, the glycine receptor. This approach circumvents two major issues: the inherent experimental difficulties in working with a...

Cite
Dawson A, Trumper P, de Souza JO, et al. Engineering a surrogate human heteromeric α/β glycine receptor orthosteric site exploiting the structural homology and stability of acetylcholine-binding protein. IUCrJ. 2019;6:1014-1023doi: 10.1107/S205225251901114X.
Dawson, A., Trumper, P., de Souza, J. O., Parker, H., Jones, M. J., Hales, T. G., & Hunter, W. N. (2019). Engineering a surrogate human heteromeric α/β glycine receptor orthosteric site exploiting the structural homology and stability of acetylcholine-binding protein. IUCrJ, 61014-1023. https://doi.org/10.1107/S205225251901114X
Dawson, Alice, et al. "Engineering a surrogate human heteromeric α/β glycine receptor orthosteric site exploiting the structural homology and stability of acetylcholine-binding protein." IUCrJ vol. 6 (2019): 1014-1023. doi: https://doi.org/10.1107/S205225251901114X
Dawson A, Trumper P, de Souza JO, Parker H, Jones MJ, Hales TG, Hunter WN. Engineering a surrogate human heteromeric α/β glycine receptor orthosteric site exploiting the structural homology and stability of acetylcholine-binding protein. IUCrJ. 2019 Sep 04;6:1014-1023. doi: 10.1107/S205225251901114X. eCollection 2019 Nov 01. PMID: 31709057; PMCID: PMC6830221.
Copy Download .nbib Format: NLM
Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia.

Complementary medicine research

Yu L, Yao Z, Wei Q, Qu M, Yang Q, Chang Y.
PMID: 33784688
Complement Med Res. 2021;28(6):516-522. doi: 10.1159/000514946. Epub 2021 Mar 30.

OBJECTIVE: We evaluated the efficacy of electroacupuncture combined with tropisetron in treating carboprost tromethamine-induced nausea and vomiting during cesarean section under lumbar anesthesia.METHODS: A total of 264 patients aged 22-40 years were enrolled, who received carboprost tromethamine and suffered...

Cite
Yu L, Yao Z, Wei Q, et al. Wirksamkeit der Elektroakupunktur in Kombination mit Tropisetron bei der Behandlung von Carboprost-Tromethamin-induzierter Übelkeit und Erbrechen während eines Kaiserschnitts in Spinalanästhesie. Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia. Complement Med Res. 2021;28(6):516-522doi: 10.1159/000514946.
Yu, L., Yao, Z., Wei, Q., Qu, M., Yang, Q., & Chang, Y. (2021). Wirksamkeit der Elektroakupunktur in Kombination mit Tropisetron bei der Behandlung von Carboprost-Tromethamin-induzierter Übelkeit und Erbrechen während eines Kaiserschnitts in Spinalanästhesie. Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia. Complementary medicine research, 28(6), 516-522. https://doi.org/10.1159/000514946
Yu, Lili, et al. "Wirksamkeit der Elektroakupunktur in Kombination mit Tropisetron bei der Behandlung von Carboprost-Tromethamin-induzierter Übelkeit und Erbrechen während eines Kaiserschnitts in Spinalanästhesie." Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia. Complementary medicine research vol. 28,6 (2021): 516-522. doi: https://doi.org/10.1159/000514946
Yu L, Yao Z, Wei Q, Qu M, Yang Q, Chang Y. Wirksamkeit der Elektroakupunktur in Kombination mit Tropisetron bei der Behandlung von Carboprost-Tromethamin-induzierter Übelkeit und Erbrechen während eines Kaiserschnitts in Spinalanästhesie. Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia. Complement Med Res. 2021;28(6):516-522. doi: 10.1159/000514946. Epub 2021 Mar 30. PMID: 33784688.
Copy Download .nbib Format: NLM
Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology: An Update.

Current medicinal chemistry

Rivera-Fonseca JL, González-Rivas N, Unnamatla MVB, García-Eleno MA, Reyes H, López-Valdez LG, Corona-Becerril D, Cuevas-Yañez E.
PMID: 34238146
Curr Med Chem. 2021 Jul 07; doi: 10.2174/0929867328666210708091134. Epub 2021 Jul 07.

An important group of anti-emetic drugs used in the treatment of nausea and vomiting after chemotherapy contains an indole moiety in their structures, working as 5-hydroxytryptamine type 3 serotonin receptor antagonist (5-HT3). This revision is focused on compounds bearing...

Cite
Rivera-Fonseca JL, González-Rivas N, Unnamatla MVB, et al. Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology: An Update. Curr Med Chem. 2021;doi: 10.2174/0929867328666210708091134.
Rivera-Fonseca, J. L., González-Rivas, N., Unnamatla, M. V. B., García-Eleno, M. A., Reyes, H., López-Valdez, L. G., Corona-Becerril, D., & Cuevas-Yañez, E. (2021). Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology: An Update. Current medicinal chemistry, . https://doi.org/10.2174/0929867328666210708091134
Rivera-Fonseca, Johana L, et al. "Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology: An Update." Current medicinal chemistry vol. (2021). doi: https://doi.org/10.2174/0929867328666210708091134
Rivera-Fonseca JL, González-Rivas N, Unnamatla MVB, García-Eleno MA, Reyes H, López-Valdez LG, Corona-Becerril D, Cuevas-Yañez E. Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology: An Update. Curr Med Chem. 2021 Jul 07; doi: 10.2174/0929867328666210708091134. Epub 2021 Jul 07. PMID: 34238146.
Copy Download .nbib Format: NLM
Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study.

Cancer management and research

Wu X, Wu J, Tong G, Cheng B, Chen M, Yu S, He L, Li Z, Wang S.
PMID: 32801895
Cancer Manag Res. 2020 Jul 29;12:6575-6583. doi: 10.2147/CMAR.S254398. eCollection 2020.

PURPOSE: Dexamethasone combined with 5-hydroxytryptamine type 3 receptor antagonists (5-HT3 RA) dual regimen is the standard prophylaxis regimen for patients receiving moderately emetogenic chemotherapy (MEC). However, it has been found in real-world practice that chemotherapy-induced nausea and vomiting (CINV)...

Cite
Wu X, Wu J, Tong G, et al. Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study. Cancer Manag Res. 2020;12:6575-6583doi: 10.2147/CMAR.S254398.
Wu, X., Wu, J., Tong, G., Cheng, B., Chen, M., Yu, S., He, L., Li, Z., & Wang, S. (2020). Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study. Cancer management and research, 126575-6583. https://doi.org/10.2147/CMAR.S254398
Wu, Xuan, et al. "Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study." Cancer management and research vol. 12 (2020): 6575-6583. doi: https://doi.org/10.2147/CMAR.S254398
Wu X, Wu J, Tong G, Cheng B, Chen M, Yu S, He L, Li Z, Wang S. Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study. Cancer Manag Res. 2020 Jul 29;12:6575-6583. doi: 10.2147/CMAR.S254398. eCollection 2020. PMID: 32801895; PMCID: PMC7402666.
Copy Download .nbib Format: NLM
Stimulatory Effect of 5-Hydroxytryptamine (5-HT) on Rat Capsaicin-Sensitive Lung Vagal Sensory Neurons via Activation of 5-HT.

Frontiers in physiology

Hsu CC, Ruan T, Lee LY, Lin YS.
PMID: 31191346
Front Physiol. 2019 May 28;10:642. doi: 10.3389/fphys.2019.00642. eCollection 2019.

5-hydroxytryptamine (5-HT) is an inflammatory mediator known to be released in lung. Capsaicin-sensitive lung vagal (CSLV) afferents function as a primary sensor for detecting chemical stimuli and produce consequent reflexes during lung inflammation. To characterize the effect of 5-HT...

Cite
Hsu CC, Ruan T, Lee LY, et al. Stimulatory Effect of 5-Hydroxytryptamine (5-HT) on Rat Capsaicin-Sensitive Lung Vagal Sensory Neurons via Activation of 5-HT. Front Physiol. 2019;10:642doi: 10.3389/fphys.2019.00642.
Hsu, C. C., Ruan, T., Lee, L. Y., & Lin, Y. S. (2019). Stimulatory Effect of 5-Hydroxytryptamine (5-HT) on Rat Capsaicin-Sensitive Lung Vagal Sensory Neurons via Activation of 5-HT. Frontiers in physiology, 10642. https://doi.org/10.3389/fphys.2019.00642
Hsu, Chun-Chun, et al. "Stimulatory Effect of 5-Hydroxytryptamine (5-HT) on Rat Capsaicin-Sensitive Lung Vagal Sensory Neurons via Activation of 5-HT." Frontiers in physiology vol. 10 (2019): 642. doi: https://doi.org/10.3389/fphys.2019.00642
Hsu CC, Ruan T, Lee LY, Lin YS. Stimulatory Effect of 5-Hydroxytryptamine (5-HT) on Rat Capsaicin-Sensitive Lung Vagal Sensory Neurons via Activation of 5-HT. Front Physiol. 2019 May 28;10:642. doi: 10.3389/fphys.2019.00642. eCollection 2019. PMID: 31191346; PMCID: PMC6546846.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 39 entries